0.078
Precedente Chiudi:
$0.08
Aprire:
$0.072
Volume 24 ore:
2.27M
Relative Volume:
0.12
Capitalizzazione di mercato:
$3.46M
Reddito:
-
Utile/perdita netta:
$-53.12M
Rapporto P/E:
-0.000717
EPS:
-108.8
Flusso di cassa netto:
$-15.86M
1 W Prestazione:
+7.59%
1M Prestazione:
+2.50%
6M Prestazione:
-88.70%
1 anno Prestazione:
-99.18%
Onconetix Inc Stock (ONCO) Company Profile
Nome
Onconetix Inc
Settore
Industria
Telefono
513-620-4101
Indirizzo
201 E. FIFTH STREET, CINCINNATI
Confronta ONCO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ONCO
Onconetix Inc
|
0.078 | 3.22M | 0 | -53.12M | -15.86M | -108.80 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Onconetix Inc Borsa (ONCO) Ultime notizie
Onconetix receives additional delisting notice from Nasdaq - Yahoo Finance
Onconetix faces potential Nasdaq delisting over filing delays By Investing.com - Investing.com Nigeria
Onconetix receives additional notice from Nasdaq - MSN
Onconetix Faces Nasdaq Delisting Notice Amid Compliance Issues - TipRanks
Onconetix faces potential Nasdaq delisting over filing delays - Investing.com Australia
Onconetix, Inc. Receives Nasdaq Delisting Letter for Failure to File Quarterly Report and Maintain Minimum Bid Price Requirements - Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewswire
Onconetix Faces Triple Threat: Nasdaq Delisting Risk Over Missing Filings and 10-Cent Stock Price - Stock Titan
Noram Receives Results for CVZ-66: High of 1540 ppm Intersection of 220ft (67.1 m) Averaging 1124 ppm of Lithium - The Globe and Mail
ONCOOnconetix Latest Stock News & Market Updates - Stock Titan
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - Barchart.com
Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan
Onconetix Inc [ONCO] Is Currently 14.45 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Onconetix Inc (ONCO) expanding its growth trajectory ahead - Sete News
ONCO Stock on the Rise: A Promising Investment - investchronicle.com
This morning’s top pick is Onconetix Inc (NASDAQ:ONCO) - uspostnews.com
Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News
ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form 8-KCurrent report - ADVFN
Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals
Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India
Onconetix faces Nasdaq delisting over low share price - Investing.com
ONCO’s current quarter earnings: What analysts forecast? - uspostnews.com
ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa
Cincinnati's Onconetix pursuing merger deal with drug development firm - The Business Journals
Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics - marketscreener.com
Onconetix eyes Ocuvex in potential merger to expand portfolio By Investing.com - Investing.com India
Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell - marketscreener.com
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - The Manila Times
Max Alderman, Partner at FE International, Recognized as a NACVA 2024 30 Under Thirty Honoree - The Manila Times
Onconetix eyes Ocuvex in potential merger to expand portfolio - Investing.com
Target Corp (TGT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan
Another top executive departs Cincinnati public firm - WKRC
Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader - The Business Journals
Onconetix Names Interim CFO Karina Fedasz as Interim CEO - MarketWatch
Onconetix Appoints Karina Fedasz as Interim CEO - TipRanks
Onconetix Delays Yearly Report Filing - TipRanks
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire
Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India
Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq
Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa
Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq
Onconetix Inc (NASDAQ: ONCO): Blank Check On Growth? - Stocks Register
Onconetix Announces New Clinical Data for its Innovative - GlobeNewswire
Onconetix to Present Proclarix at EAU Congress 2025 - TipRanks
Onconetix Inc Azioni (ONCO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):